SCHEMBL4173246

SCHEMBL4173246

CN(c1ccc2c(c1)OCO2)c1ncccc1-c1nnc(-c2cccc(C(F)(F)F)c2)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.39
CLK2 P49760 1/20 0.39
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
HRH1 P35367 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
KDR P35968 3/20 0.37
SCN2A Q99250 2/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
GAA P10253 1/20 0.35
CYP2D6 P10635 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
EGFR P00533 1/20 0.35
PDGFRB P09619 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179118 0.91 MAP2K4 (0.37) CLK1CLK2DYRK1ACLK4DYRK1B
SCHEMBL4174803 0.88 KDR (0.37) CLK4KDRLMNACYP1A2GAA
SCHEMBL4181161 0.86 KDR (0.38) CLK1CLK2DYRK1ACLK4DYRK1B
SCHEMBL4174287 0.85 MAPT (0.41) DYRK1ACLK4KDRALDH1A1LMNA
SCHEMBL4523019 0.83 NPY5R (0.42) HRH1HRH4KDRSCN2AALDH1A1
SCHEMBL4173818 0.82 CLK4 (0.38) DYRK1ACLK4KDRALDH1A1LMNA
SCHEMBL4181575 0.81 KIT (0.42) HRH1KDRALDH1A1LMNACYP1A2
SCHEMBL4173249 0.79 PTGS2 (0.42) KDRKMT2AEGFRPDGFRBPDGFRA
SCHEMBL4176750 0.77 MAP2K4 (0.39) CLK1CLK2DYRK1ACLK4DYRK1B
SCHEMBL4173239 0.76 KDR (0.52) CLK1DYRK1ACLK4KDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL CLK1 3749/4885CLK2 3057/4885DYRK1A 4792/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL CLK1 3749/4885CLK2 3057/4885DYRK1A 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.